Hong Kong · Delayed Price · Currency is HKD Shanghai Bio-heart Biological Technology Company Description
Shanghai Bio-heart Biological Technology Co., Ltd. an interventional cardiovascular device company, engages in the research and development of therapies for unmet medical needs of patients in the People’s Republic of China.
The company develops Bioheart, a bioresorbable scaffolds (BRS) system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a renal denervation (RDN) product candidate for the treatment of uncontrolled hypertension and resistant hypertension; and drug coated balloon (DCB), a sirolimus drug-eluting balloon catheter designed for instent restenosis.
Shanghai Bio-heart Biological Technology Co., Ltd. was founded in 2014 and is headquartered in Shanghai, the People’s Republic of China.
| Country | China |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Li Wang |
Contact Details
Address: Building 4 Shanghai China | |
| Phone | 86 21 6879 8511 |
| Website | bio-heart.com |
Stock Details
| Ticker Symbol | 2185 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100004JH3 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Li Wang | Executive Chairman of the Board, Chief Executive Officer and GM |
| Yunqing Wang | Chief Financial Officer, Joint Company Secretary and Executive Director |
| Peili Wang | Financial Manager and Executive Director |
| Dr. Bradley Stewart Hubbard D.V.M., DVM | Chief Medical Officer |
| Siu Ying Kwok | Joint Company Secretary |
| Tao Cai | Chairperson of the Board of Supervisors and Head of Technology of BRS |